

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

One stakeholder highlighted that children from lower socioeconomic backgrounds may be disproportionately affected by birch tree pollen allergies because of higher pollution exposure, limited access to avoidance measures and barriers to access of specialist care. They suggested that these factors may lead to poorer symptom control, reduced school performance, and fewer future opportunities.
--

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

In line with other technology appraisals in allergic rhinitis and conjunctivitis, these equality issues will be considered by the committee during the evaluation.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Associate Director: ...Emily Crowe

Date: 22/10/2025